Ann: ADVENT-AML Phase 1B clinical trial update, page-19

Surely the point from an investor's point of view is to hold now until the 20 patients have been entered into the trial and with this success it's apparent this won't take long. If you had AML wouldn't you line up tomorrow if you met the entry criteria? The same success rate maintained over the trial, and a sustained response for those already treated is what we wait on. $9 million for this company will then seem a distant memory. Though this comes with risk, the zeroing in of the Science onto the disease cells is the very factor lessening said risk.